Actualités et vidéos - KIADIS - Page 4

Kiadis will focus all future investments on developing off-the-shelf and haplo donor NK-cell therapies for the treatment of solid and liquid tumors Discontinues development of ATIR101, stopping phase 3 trial Restructures organization; reducing workforce by approximately half Amsterdam, The Netherlands, 12 November 2019 – Kiadis Pharma N.V. (“ Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announced that it has...

ASH Abstract # ATIR101: 592, 4464; NK-cell Therapy (K-NK002) 1955 Phase II data analysis of ATIR101 as an adjunctive treatment following T-cell depleted haploidentical hematopoietic stem cell transplantation Trial-in-progress overviews of Phase III ATIR101 and Phase II NK-cell Therapy (K-NK002) clinical trial programs Amsterdam, The Netherlands, November 6, 2019 – Kiadis Pharma N.V. (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces abstracts...

Amsterdam, The Netherlands, November 5, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that the Kiadis management team will present and will host meetings at the following conferences in November 2019. FT Global Pharmaceuticals and Biotechnology Summit November 12, 2019, London, UK Arthur Lahr, Chief Executive Officer, will participate in a panel discussion related to ‘...

Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts in the field of oncology and cell therapy. The SAB will provide invaluable scientific expertise and guidance to the Kiadis management team and Board, as the Company progresses its two synergistic...

Kiadis no longer expects EU conditional marketing authorization for ATIR101 in 2020 Kiadis plans to refile at the conclusion of the ongoing phase 3 trial Amsterdam, The Netherlands, 17 October 2019 – Kiadis Pharma N.V. (“ Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announced that it no longer expects to receive EU conditional marketing authorization for ATIR101 in 2020. The Company expects that European...

Kiadis to hold conference call with investors today at 15:00 CEST Amsterdam, The Netherlands, September 10, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces its unaudited interim results for the six months ended June 30, 2019, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. Arthur Lahr, CEO of...

 Company announces Notice of Results for the six months ended June 30, 2019 Amsterdam, The Netherlands, August 19, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, announces its investor events in September 2019. Interim results Kiadis will be issuing its interim results for the six months ended June 30, 2019 at 7.00am CEST / 6.00am BST / 1.00am EDT on Tuesday, September 10, 2019....

Kiadis Pharma to present at upcoming conference in August 2019 Amsterdam, The Netherlands, July 31, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces it is scheduled to attend the following conference in August 2019. Cannacord Genuity 39 th Annual Growth Conference August 7-8, 2019, Boston, MA Management will present on August 7 th at 09.00-09.25am EDT and will host meetings....

Kiadis updates status of marketing authorization application for ATIR101 Amsterdam, The Netherlands, June 28, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has received feedback from the European Medicines Agency (EMA) related to the marketing authorization application (MAA) seeking approval of ATIR101 in hematopoietic stem cell transplant (HSCT). As previously announced, Kiadis...

Kiadis Pharma Announces Results Annual General Meeting Amsterdam, The Netherlands, June 24, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, announces that at its Annual General Meeting held today at 10:00 CEST at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands, all resolutions were duly passed by the shareholders. For more information, please contact: Kiadis...

Amsterdam, The Netherlands, June 6, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that it has closed the previously announced acquisition of CytoSen Therapeutics, Inc. ("CytoSen"). The transaction creates a leader in cell-based cancer immunotherapy with proprietary and synergistic NK-cell and T-cell therapy platforms that have the potential to revolutionize HSCT and create a pipeline with...

Kiadis Pharma to present at upcoming conferences in June 2019 Amsterdam, The Netherlands, June 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces it is scheduled to attend the following conferences in June 2019. Jefferies 2019 Global Healthcare Conference June 4-7, 2019, New York, US Management will present on June 4 th at 4:00pm EDT and will host meetings with institutional...

Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, south africa or Any other jurisdiction in which such release, publication or distribution would be unlawful Kiadis Pharma raises c.EUR 28 million in a private placement of c.3.7 million new shares Amsterdam, The Netherlands, May 31, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical...

Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, south africa or Any other jurisdiction in which such release, publication or distribution would be unlawful Kiadis Pharma launches a private placement of new shares to raise approximately EUR 25 million Amsterdam, The Netherlands, May 30, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage...

Amsterdam, The Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that at its Extraordinary General Meeting of shareholders held today at 10:00 CEST at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands, the resolution to approve the acquisition of CytoSen Therapeutics, Inc. - the sole proposal on the agenda - was duly passed by...

Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency's (EMA) second Day 180 list of outstanding issues for ATIR101. Kiadis submitted a marketing authorization application (MAA) to the EMA in 2017 seeking approval of ATIR101 as an adjunctive immunotherapy for hematopoietic stem cell...

Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 - Be The Match BioTherapies ®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Kiadis Pharma N.V. ("Kiadis") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announced a strategic collaboration to support clinical evaluation of an innovative cell...

Amsterdam, The Netherlands, 13 May 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting ("AGM") of shareholders will be held at 10:00 CEST on 24 June 2019 at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands. The notice and agenda for the AGM as well as the proxy form are available on the Investors' section of the...

Amsterdam, The Netherlands, 30 April 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces its audited 2018 Annual Results for the year ended December 31, 2018, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. Arthur Lahr, CEO of Kiadis Pharma, commented: "Kiadis made significant progress in 2018 as we continue...

Amsterdam, The Netherlands, April 17, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraordinary general meeting of shareholders (" EGM ") to obtain shareholder approval pursuant to section 2:107a of the Dutch Civil Code for the proposed acquisition of CytoSen Therapeutics, Inc. that was announced earlier today. The EGM is to be held on Wednesday, May 29,...